Scandion Oncology A/S (SCOL.ST)
Scandion Oncology A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Copenhagen, DK. The stock last traded at $0.00, down 39.71% on the session, giving a market capitalisation of $962,520. Its beta of 1.86 implies it has historically moved more than the broad market.
Operating as a clinical-stage biotechnology company, Scandion Oncology A/S specializes in creating pharmaceutical solutions to combat resistance to chemotherapy. Their primary investigational drug, SCO-101, an orally administered compound, is currently progressing through Phase Ib and Phase II clinical studies with cancer patients. Another pipeline candidate, SCO-201, is undergoing preclinical assessment for its potential efficacy against solid tumors. Established in 2017, Scandion Oncology A/S maintains its headquarters in Copenhagen, Denmark.
Scandion Oncology A/S is most often compared with the following Healthcare names: